Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors. To estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC. Participants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.


Clinical Trial Description

The investigators are asking the participant to take part in this research study because they were diagnosed with a kidney tumor. Kidney tumors can be benign (not cancer) or malignant (cancer) and the investigators hope to figure out how to better tell them apart before surgery or other treatment. The investigators hope to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. Biopsy is a standard test to determine if a tumor is cancerous before making a treatment decision. The imaging test (99mTc-sestamibi SPECT/CT) the investigators are studying has been studied before and found to help identify benign kidney tumors. It is not approved by the Food and Drug Administration (FDA) for imaging kidney tumors. It is FDA approved for use in imaging the heart and breasts. It has been studied for use in parathyroid gland imaging. The participant will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. The participant will receive a 99mTc-sestamibi SPECT/CT scan (if they have not had one already) for research purposes. The participant will receive a biopsy of the kidney tumor (if they have not had one already) as part of their routine clinical care. The participant will then receive treatment of the kidney tumor as determined by consultation with their doctor. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05728957
Study type Observational
Source Loyola University
Contact Gopal N Gupta, MD
Phone 708-216-8467
Email gogupta@lumc.edu
Status Recruiting
Phase
Start date February 1, 2023
Completion date December 2033

See also
  Status Clinical Trial Phase
Completed NCT01950923 - Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer Phase 1
Withdrawn NCT01688414 - Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer N/A
Recruiting NCT05387863 - Decision Aid (DA) for Renal Patients N/A
Active, not recruiting NCT03819569 - GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses N/A
Recruiting NCT06056505 - Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy N/A
Recruiting NCT01967407 - IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy. Phase 1/Phase 2
Terminated NCT00960063 - A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) Phase 1
Recruiting NCT05890781 - Engineering Immune Organoids to Study Pediatric Cancer N/A
Completed NCT05015179 - Mixed Reality Technology in Laparoscopic Partial Nephrectomy N/A
Completed NCT00019630 - Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Phase 1
Completed NCT01908166 - Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions N/A